Do analysts prefer ALMR or STVN?

Alamar Biosciences currently has a consensus price target of $31.80, indicating a potential downside of 3.75%. Given Alamar Biosciences' higher probable upside, analysts plainly believe Alamar Biosciences is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alamar Biosciences 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media favor ALMR or STVN?

In the previous week, Alamar Biosciences had 3 more articles in the media than Stevanato Group. MarketBeat recorded 17 mentions for Alamar Biosciences and 14 mentions for Stevanato Group. Alamar Biosciences' average media sentiment score of 0.57 beat Stevanato Group's score of 0.53 indicating that Alamar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 2 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALMR or TXG?

In the previous week, Alamar Biosciences had 2 more articles in the media than 10x Genomics. MarketBeat recorded 17 mentions for Alamar Biosciences and 15 mentions for 10x Genomics. Alamar Biosciences' average media sentiment score of 0.57 beat 10x Genomics' score of 0.57 indicating that Alamar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 2 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 5 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALMR or TWST?

In the previous week, Alamar Biosciences had 3 more articles in the media than Twist Bioscience. MarketBeat recorded 17 mentions for Alamar Biosciences and 14 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 0.64 beat Alamar Biosciences' score of 0.57 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 2 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 4 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALMR or SHC?

In the previous week, Alamar Biosciences and Alamar Biosciences both had 17 articles in the media. Sotera Health's average media sentiment score of 0.69 beat Alamar Biosciences' score of 0.57 indicating that Sotera Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 2 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sotera Health 5 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CAI or ALMR?

In the previous week, Alamar Biosciences had 9 more articles in the media than Caris Life Sciences. MarketBeat recorded 17 mentions for Alamar Biosciences and 8 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.85 beat Alamar Biosciences' score of 0.57 indicating that Caris Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 2 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alamar Biosciences (ALMR) Competitors

$33.04 +0.12 (+0.36%)

As of 02:16 PM Eastern

Compare

ALMR vs. STVN, TXG, TWST, SHC, and CAI

Should you buy Alamar Biosciences stock or one of its competitors? Alamar Biosciences's main competitors and comparable companies include Stevanato Group (STVN), 10x Genomics (TXG), Twist Bioscience (TWST), Sotera Health (SHC), and Caris Life Sciences (CAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Alamar Biosciences compare to Stevanato Group?

Alamar Biosciences (NASDAQ:ALMR) and Stevanato Group (NYSE:STVN) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Alamar Biosciences currently has a consensus price target of $31.80, indicating a potential downside of 3.75%. Given Alamar Biosciences' higher probable upside, analysts plainly believe Alamar Biosciences is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Alamar Biosciences had 3 more articles in the media than Stevanato Group. MarketBeat recorded 17 mentions for Alamar Biosciences and 14 mentions for Stevanato Group. Alamar Biosciences' average media sentiment score of 0.57 beat Stevanato Group's score of 0.53 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	2 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Stevanato Group has a net margin of 10.99% compared to Alamar Biosciences' net margin of 0.00%. Stevanato Group's return on equity of 10.43% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Stevanato Group	10.99%	10.43%	6.16%

Stevanato Group has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	30.89	-$29.82M	-$1.74	N/A
Stevanato Group	€1.34B	4.76	€158.21M	€0.56	37.68

Summary

Stevanato Group beats Alamar Biosciences on 9 of the 14 factors compared between the two stocks.

How does Alamar Biosciences compare to 10x Genomics?

Alamar Biosciences (NASDAQ:ALMR) and 10x Genomics (NASDAQ:TXG) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Alamar Biosciences has a net margin of 0.00% compared to 10x Genomics' net margin of -12.18%. Alamar Biosciences' return on equity of 0.00% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
10x Genomics	-12.18%	-9.41%	-7.31%

Alamar Biosciences currently has a consensus price target of $31.80, suggesting a potential downside of 3.75%. 10x Genomics has a consensus price target of $38.31, suggesting a potential downside of 32.48%. Given Alamar Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Alamar Biosciences is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25

84.7% of 10x Genomics shares are held by institutional investors. 8.8% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alamar Biosciences has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	30.89	-$29.82M	-$1.74	N/A
10x Genomics	$642.82M	11.21	-$43.54M	-$0.59	N/A

In the previous week, Alamar Biosciences had 2 more articles in the media than 10x Genomics. MarketBeat recorded 17 mentions for Alamar Biosciences and 15 mentions for 10x Genomics. Alamar Biosciences' average media sentiment score of 0.57 beat 10x Genomics' score of 0.57 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	2 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
10x Genomics	5 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alamar Biosciences beats 10x Genomics on 10 of the 15 factors compared between the two stocks.

How does Alamar Biosciences compare to Twist Bioscience?

Alamar Biosciences (NASDAQ:ALMR) and Twist Bioscience (NASDAQ:TWST) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Alamar Biosciences presently has a consensus price target of $31.80, indicating a potential downside of 3.75%. Twist Bioscience has a consensus price target of $98.30, indicating a potential downside of 17.95%. Given Alamar Biosciences' higher possible upside, research analysts plainly believe Alamar Biosciences is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Alamar Biosciences had 3 more articles in the media than Twist Bioscience. MarketBeat recorded 17 mentions for Alamar Biosciences and 14 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 0.64 beat Alamar Biosciences' score of 0.57 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	2 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	4 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alamar Biosciences has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	30.89	-$29.82M	-$1.74	N/A
Twist Bioscience	$376.57M	19.95	-$77.67M	-$2.22	N/A

Alamar Biosciences has a net margin of 0.00% compared to Twist Bioscience's net margin of -31.66%. Alamar Biosciences' return on equity of 0.00% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Twist Bioscience	-31.66%	-28.64%	-19.94%

Summary

Alamar Biosciences beats Twist Bioscience on 9 of the 13 factors compared between the two stocks.

How does Alamar Biosciences compare to Sotera Health?

Alamar Biosciences (NASDAQ:ALMR) and Sotera Health (NASDAQ:SHC) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Sotera Health has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	30.89	-$29.82M	-$1.74	N/A
Sotera Health	$1.16B	4.63	$77.94M	$0.57	33.10

Sotera Health has a net margin of 13.44% compared to Alamar Biosciences' net margin of 0.00%. Sotera Health's return on equity of 40.12% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Sotera Health	13.44%	40.12%	7.55%

91.0% of Sotera Health shares are owned by institutional investors. 15.4% of Sotera Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alamar Biosciences currently has a consensus target price of $31.80, indicating a potential downside of 3.75%. Sotera Health has a consensus target price of $21.50, indicating a potential upside of 13.97%. Given Sotera Health's stronger consensus rating and higher probable upside, analysts clearly believe Sotera Health is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Alamar Biosciences and Alamar Biosciences both had 17 articles in the media. Sotera Health's average media sentiment score of 0.69 beat Alamar Biosciences' score of 0.57 indicating that Sotera Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	2 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sotera Health	5 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sotera Health beats Alamar Biosciences on 13 of the 14 factors compared between the two stocks.

How does Alamar Biosciences compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Alamar Biosciences (NASDAQ:ALMR) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Alamar Biosciences has lower revenue, but higher earnings than Caris Life Sciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$348.89M	17.62	-$68.09M	$0.36	60.44
Alamar Biosciences	$74.21M	30.89	-$29.82M	-$1.74	N/A

In the previous week, Alamar Biosciences had 9 more articles in the media than Caris Life Sciences. MarketBeat recorded 17 mentions for Alamar Biosciences and 8 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.85 beat Alamar Biosciences' score of 0.57 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	2 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences has a net margin of 10.62% compared to Alamar Biosciences' net margin of 0.00%. Caris Life Sciences' return on equity of 18.77% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Alamar Biosciences	N/A	N/A	N/A

Caris Life Sciences currently has a consensus target price of $26.33, indicating a potential upside of 21.03%. Alamar Biosciences has a consensus target price of $31.80, indicating a potential downside of 3.75%. Given Caris Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Caris Life Sciences is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Caris Life Sciences beats Alamar Biosciences on 10 of the 13 factors compared between the two stocks.

Get Alamar Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALMR vs. The Competition

Export

Metric	Alamar Biosciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.29B	$9.47B	$6.98B	$13.02B
Dividend Yield	N/A	1.46%	2.58%	10.72%
P/E Ratio	-18.99	60.43	269.27	25.24
Price / Sales	30.89	105.58	597.12	100.97
Price / Cash	N/A	26.03	70.53	50.75
Price / Book	N/A	38.09	13.06	6.33
Net Income	-$29.82M	$56.66B	$3.45B	$347.70M
7 Day Performance	16.09%	0.42%	0.91%	0.94%
1 Month Performance	22.14%	1.68%	1.59%	0.90%
1 Year Performance	N/A	19.63%	67.34%	20.38%

Alamar Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALMR Alamar Biosciences	1.072 of 5 stars	$33.04 +0.4%	$31.80 -3.8%	N/A	$2.29B	$74.21M	N/A	222	News Coverage Earnings Report Analyst Forecast
STVN Stevanato Group	3.5743 of 5 stars	€19.89 -1.5%	N/A	-3.5%	€6.01B	€1.34B	33.71	6,010	Positive News
TXG 10x Genomics	1.7203 of 5 stars	$47.27 -4.4%	$32.08 -32.1%	+328.5%	$6.00B	$642.82M	N/A	1,240	Analyst Forecast Insider Trade
TWST Twist Bioscience	1.3593 of 5 stars	$91.55 +0.2%	$90.30 -1.4%	+337.3%	$5.70B	$376.57M	N/A	990	Insider Trade
SHC Sotera Health	4.0995 of 5 stars	$17.86 +0.1%	$20.25 +13.4%	+21.0%	$5.09B	$1.16B	43.56	3,000	Positive News Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALMR) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alamar Biosciences (ALMR) Competitors

ALMR vs. STVN, TXG, TWST, SHC, and CAI

How does Alamar Biosciences compare to Stevanato Group?

Summary

How does Alamar Biosciences compare to 10x Genomics?

Summary

How does Alamar Biosciences compare to Twist Bioscience?

Summary

How does Alamar Biosciences compare to Sotera Health?

Summary

How does Alamar Biosciences compare to Caris Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMR vs. The Competition

Alamar Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alamar Biosciences (ALMR) Competitors

ALMR vs. STVN, TXG, TWST, SHC, and CAI

How does Alamar Biosciences compare to Stevanato Group?

Do analysts prefer ALMR or STVN?

Does the media favor ALMR or STVN?

Is ALMR or STVN more profitable?

Which has better earnings and valuation, ALMR or STVN?

Summary

How does Alamar Biosciences compare to 10x Genomics?

Is ALMR or TXG more profitable?

Do analysts rate ALMR or TXG?

Do insiders & institutionals have more ownership in ALMR or TXG?

Which has better earnings and valuation, ALMR or TXG?

Does the media prefer ALMR or TXG?

Summary

How does Alamar Biosciences compare to Twist Bioscience?

Do analysts rate ALMR or TWST?

Does the media prefer ALMR or TWST?

Which has higher valuation and earnings, ALMR or TWST?

Is ALMR or TWST more profitable?

Summary

How does Alamar Biosciences compare to Sotera Health?

Which has preferable earnings & valuation, ALMR or SHC?

Is ALMR or SHC more profitable?

Do institutionals and insiders have more ownership in ALMR or SHC?

Do analysts rate ALMR or SHC?

Does the media favor ALMR or SHC?

Summary

How does Alamar Biosciences compare to Caris Life Sciences?

Which has higher valuation & earnings, CAI or ALMR?

Does the media favor CAI or ALMR?

Is CAI or ALMR more profitable?

Do analysts recommend CAI or ALMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMR vs. The Competition

Alamar Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools